10X GENOMICS INC-CLASS A
TXGNASDAQTrading Snapshot
- Day Range
- $78.62 β $87.72
- 52-Week Range
- $12.34 β $102.81
- Volume (shares)
- 406,533
- Avg Volume (shares)
- β
- Shares Outstanding
- 130.3M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $643M
- Last Q Revenue
- $151M
- P/E Ratio
- β
- P/S Ratio
- 16.6x
- EPS (TTM)
- $-0.59
- Dividend Yield
- β
- Dilution (1yr)
- +4.5%
10X GENOMICS INC-CLASS A
TXGAbout 10X GENOMICS INC-CLASS A
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.